A phase 1a/1b study to evaluate TT-10 in patients with advanced solid tumors both as a monotherapy and in combination with other anti-cancer agents
Latest Information Update: 28 Jul 2021
At a glance
- Drugs PORT-6 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 28 Jul 2021 New trial record